Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pathology & Oncology Research
Erschienen in: Pathology & Oncology Research 3/2020

06.12.2019 | Review

TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma

verfasst von: Antonio Travaglino, Antonio Raffone, Massimo Mascolo, Maurizio Guida, Luigi Insabato, Gian Franco Zannoni, Fulvio Zullo

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

We aimed to classify undifferentiated/dedifferentiated carcinoma (UDC/DDC) according to the four TCGA molecular subgroups of endometrial cancer: microsatellite-instable/hypermutated (MSI), POLE-mutant/ultramutated (POLE), copy-number-low/p53-wild-type (p53wt), and copy-number-high/p53-abnormal (p53abn), through a systematic review and meta-analysis. Electronic databases were searched from January 2013 to July 2019 for studies assessing the TCGA classification in endometrial UDC/DDC series. Pooled prevalence of each TCGA subgroup on the total UDC/DDCs was calculated. Three studies with 73 patients were included. Pooled prevalence of the TCGA subgroups were: 12.4% for the POLE subgroup, 44% for the MSI subgroup, 18.6% for the p53abn subgroup, 25% for the p53wt group. All TCGA groups are represented in UDC/DDC, with a predominance of the MSI group, indicating a biological heterogeneity. Hypermutated/ultramutated cancers constitute the majority of UDC/DDC, suggesting a crucial difference with other high-risk histologies of endometrial carcinoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29PubMed
2.
Travaglino A, Raffone A, Saccone G et al (2019) Immunohistochemical nuclear expression of β-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial Cancer. Am J Clin Pathol 151(5):529–538CrossRefPubMed
3.
4.
5.
Travaglino A, Raffone A, Saccone G et al (2019) Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. https://​doi.​org/​10.​1111/​aogs.​13587
6.
Cancer Genome Atlas Research Network et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73CrossRef
7.
Stelloo E, Nout RA, Osse EM et al (2016) Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 22(16):4215–4224CrossRefPubMed
8.
Bosse T, Nout RA, McAlpine JN et al (2018) Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol 42(5):561–568PubMedPubMedCentral
9.
Cosgrove CM, Tritchler DL, Cohn DE et al (2018 Jan) An NRG oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. GynecolOncol. 148(1):174–180
10.
Talhouk A, McConechy MK, Leung S et al (2015) A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 113(2):299–310CrossRefPubMedPubMedCentral
11.
Talhouk A, McConechy MK, Leung S et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 123(5):802–813CrossRefPubMed
12.
Kommoss S, McConechy MK, Kommoss F et al (2018 May 1) Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. AnnOncol. 29(5):1180–1188
13.
Hoang LN, Kinloch MA, Leo JM et al (2017 Feb) Interobserver agreement in endometrial carcinoma Histotype diagnosis varies depending on the Cancer genome atlas (TCGA)-based molecular subgroup. Am J Surg Pathol 41(2):245–252CrossRefPubMed
14.
15.
Lionetti R, De Luca M, Travaglino A et al (2019 Jul) Treatments and overall survival in patients with Krukenberg tumor. Arch Gynecol Obstet 300(1):15–23CrossRefPubMed
16.
17.
Raffone A, Travaglino A, Saccone G et al (2019) Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. https://​doi.​org/​10.​1111/​aogs.​13586
18.
19.
Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 4:1CrossRefPubMedPubMedCentral
20.
Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536CrossRefPubMed
21.
22.
Raffone A, Travaglino A, Saccone G et al (2019) PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 299(6):1511–1524CrossRefPubMed
23.
24.
Travaglino A, Raffone A, Saccone G et al (2019) PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS 127(4):161–169CrossRefPubMed
25.
Raffone A, Travaglino A, Saccone G et al (2019) Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet 299(5):1233–1242CrossRefPubMed
26.
27.
28.
29.
30.
Meng B, Hoang LN, McIntyre JB et al (2014) POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 134(1):15–19CrossRefPubMed
31.
Stewart CJ, Crook ML (2015) SWI/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma. Pathology. 47(5):439–445CrossRefPubMed
32.
Coatham M, Li X, Karnezis AN et al (2016) Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Mod Pathol 29(12):1586–1593CrossRefPubMed
33.
Ramalingam P, Croce S, McCluggage WG (2017) Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology. Histopathology. 70(3):359–366CrossRefPubMed
34.
Rosa-Rosa JM, Leskelä S, Cristóbal-Lana E et al (2016) Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. Mod Pathol 29(11):1390–1398CrossRefPubMedPubMedCentral
35.
Espinosa I, Lee CH, D’Angelo E, Palacios J, Prat J (2017) Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Am J Surg Pathol 41(8):1121–1128CrossRefPubMed
36.
Köbel M, Hoang LN, Tessier-Cloutier B et al (2018) Undifferentiated endometrial carcinomas show frequent loss of core switch/sucrose nonfermentable complex proteins. Am J Surg Pathol 42(1):76–83PubMedPubMedCentral
37.
Murali R, Davidson B, Fadare O et al (2019) High-grade endometrial carcinomas: morphologic and Immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol 38 Suppl 1:S40–S63CrossRefPubMed
38.
Silverberg SG, Nogales F, Tavassoli FA, Devilee P (eds) (2003) Tumours of the uterine corpus. Pathology and genetics: Tumours of the breast and female genital organs. IARC Press. World Health Organization Classification of Tumours, Lyon, pp 217–257
39.
Zaino R, Carinelli SG, Eng C, Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds) (2014) Tumours of the uterine corpus. WHO classification of tumours of female reproductive organs. IARC Press. World Health Organization Classification of Tumours, Lyon, pp 121–154
40.
Karnezis AN, Hoang LN, Coatham M et al (2016) Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol 29:302–314CrossRefPubMedPubMedCentral
41.
Abu-Rustum NR, Yashar CM, Bean S, et al (2019) NCCN clinical practice guidelines in oncology (NCCN Guidelines®) – Uterine Neoplasms. Version 3.Feb 11 2019
42.
Stelloo E, Bosse T, Nout RA et al (2015) Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 28(6):836–844CrossRefPubMed
43.
44.
45.
Goodman AM, Kato S, Bazhenova L et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16(11):2598–2608CrossRefPubMedPubMedCentral
Metadaten
Titel
TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma
verfasst von
Antonio Travaglino
Antonio Raffone
Massimo Mascolo
Maurizio Guida
Luigi Insabato
Gian Franco Zannoni
Fulvio Zullo
Publikationsdatum
06.12.2019
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00784-0

Weitere Artikel der Ausgabe 3/2020

Pathology & Oncology Research 3/2020 Zur Ausgabe

Original Article

Mcl-1 Inhibitor Induces Cells Death in BRAF-Mutant Amelanotic Melanoma Trough GSH Depletion, DNA Damage and Cell Cycle Changes

Original Article

Neuroendocrine Cancer of the Prostate

Original Article

EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy

Original Article

Genetic Polymorphisms in the Vitamin D Pathway and Non-small Cell Lung Cancer Survival

Original Article

Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients

Short Communication

Tight Junction-Related CLDN5 and CLDN6 Genes, and Gap Junction-Related GJB6 and GJB7 Genes Are Somatically Mutated in Gastric and Colorectal Cancers

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise